{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.194306","value":"0.22697"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.302378","value":"0.43848"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"90"}],"units":"Participants"}],"title":"Week 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.527741","value":"0.14038"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"}],"units":"Participants"}],"title":"Week 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.172524","value":"0.03205"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"86"}],"units":"Participants"}],"title":"Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.055724","value":"0.01044"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"}],"units":"Participants"}],"title":"Week 16"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.027446","value":"0.00476"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"}],"units":"Participants"}],"title":"Week 20"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.011041","value":"0.00291"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"}],"units":"Participants"}],"title":"Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.010182","value":"0.00209"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"}],"units":"Participants"}],"title":"Week 36"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.007022","value":"0.00149"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"78"}],"units":"Participants"}],"title":"Week 48"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.006373","value":"0.00120"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"}],"units":"Participants"}],"title":"Week 60"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.003366","value":"0.00098"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"}],"units":"Participants"}],"title":"Week 72"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.006416","value":"0.00120"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"70"}],"units":"Participants"}],"title":"Week 84"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.010148","value":"0.00169"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"}],"units":"Participants"}],"title":"Week 96"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.032543","value":"0.00492"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"70"}],"units":"Participants"}],"title":"Week 108"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.002945","value":"0.00073"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"65"}],"units":"Participants"}],"title":"Week 120"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.002217","value":"0.00055"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"65"}],"units":"Participants"}],"title":"Week 132"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.002429","value":"0.00068"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"}],"units":"Participants"}],"title":"Week 144"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.003559","value":"0.00074"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"}],"units":"Participants"}],"title":"Week 156"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.003267","value":"0.00071"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"}],"units":"Participants"}],"title":"Week 168"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.001156","value":"0.00047"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"}],"units":"Participants"}],"title":"Week 180"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.016285","value":"0.00262"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"}],"units":"Participants"}],"title":"Week 192"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.126293","value":"0.01753"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"}],"units":"Participants"}],"title":"Week 204"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.048460","value":"0.00683"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"}],"units":"Participants"}],"title":"Week 216"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.029012","value":"0.00427"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"title":"Week 228"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.016585","value":"0.00315"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"title":"Week 240"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.029570","value":"0.00660"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"title":"Week 252"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.061134","value":"0.01436"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"}],"units":"Participants"}],"title":"Week 264"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.081702","value":"0.01784"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"title":"Week 276"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.098699","value":"0.01616"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"}],"units":"Participants"}],"title":"Week 288"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.113939","value":"0.01865"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"}],"units":"Participants"}],"title":"Week 300"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.124114","value":"0.02516"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"title":"Week 312"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.113715","value":"0.01939"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"title":"Week 324"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.078374","value":"0.01348"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"title":"Week 336"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.045810","value":"0.00801"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"title":"Week 348"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.057496","value":"0.01015"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"title":"Week 360"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.028312","value":"0.00509"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"title":"Week 372"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.010247","value":"0.00206"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"title":"Week 384"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.006892","value":"0.00137"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"title":"Week 396"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.007350","value":"0.00158"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"}],"units":"Participants"}],"title":"Week 408"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.008446","value":"0.00171"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"title":"Week 420"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.004642","value":"0.00102"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"title":"Week 432"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.002430","value":"0.00057"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"title":"Week 444"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.002877","value":"0.00084"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"title":"Week 456"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.003204","value":"0.00083"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"title":"Week 468"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.156501","value":"0.03371"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"title":"Week 480"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.002046","value":"0.00062"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"title":"Week 492"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.001246","value":"0.00044"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"title":"Week 504"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.001920","value":"0.00073"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"title":"Week 516"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"Week 528"}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"}],"units":"Participants"}],"description":"The BCR-ABL ratio (%) represents the level of BCR-ABL fusion gene transcripts relative to a control gene (ABL) measured in peripheral blood samples using quantitative reverse transcription polymerase chain reaction (RT-PCR). Results are expressed as a percentage on the International Scale (IS), a standardized reporting method that allows comparison across laboratories. The BCR-ABL ratio is used to assess the molecular response to treatment, with lower values indicating a reduced disease burden.","dispersionType":"Standard Deviation","groups":[{"description":"Participants who experienced loss of major molecular response during the treatment-free remission (TFR) phase entered the nilotinib treatment re-initiation (NTRI) phase. During this phase, nilotinib treatment was re-initiated at a dose of 300 mg twice daily.","id":"OG000","title":"NTRI Phase"}],"paramType":"MEAN","populationDescription":"The nilotinib treatment re-initiation (NTRI) safety set included all participants who received at least one dose of study medication during the nilotinib treatment re-initiation phase.","reportingStatus":"POSTED","timeFrame":"Baseline; every 4 weeks up to Week 24; and every 12 weeks thereafter, up to Week 528","title":"BCR-ABL Ratio (%) Over Time in Nilotinib Treatment Re-initiation Phase (NTRI)","type":"SECONDARY","unitOfMeasure":"Percent"}